Principal Scientist, Clinical Biomarker, Immunology, Immuno-Oncology, & Hematology (Contractor)

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three RD sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma. Legend Biotech is seeking a Principal Scientist, Clinical Biomarker, Immunology, Immuno-Oncology, Hematology (Contractor) as part of the Research Development team based in Somerset, NJ. Role Overview We are seeking a highly motivated and innovative Principal Scientist to join our immunology and immuno-oncology (IO) clinical biomarker projects, with a dedicated focus on hematological malignancies. In this role, you will drive the clinical translational understanding of novel therapy in hematology. You will serve as the biology lead on cross-functional project teams, drive MOA of novel cell therapy and clinical biomarker strategy. Contract Duration: 12 months Key Responsibilities Scientific Leadership: Design, execute, and analysis results from clinical studies to investigate the mechanisms of action for novel IO targets in hematological indications (e.g., AML, DLBCL, Multiple Myeloma). Translational Strategy: Bridge discovery and clinical development by utilizing primary human samples and clinical datasets to validate targets and understand the immune microenvironment in hematology. Understanding MOA: Oversee the generation and interpretation of high-dimensional molecular and cellular data. Leverage advanced single-cell technologies (e.g., scRNA-seq) to deeply profile immune cell compartments, particularly T-cell states and exhaustion markers, to inform patient stratification and biomarker hypotheses. Cross-Functional Collaboration: Partner closely with other functional teams for better understanding of MOA and fundamental immunology Requirements Ph.D. in Immunology, Immuno-Oncology, Cellular Biology, or a closely related discipline, can initiate and lead data driven MOA studies. Experience with cell therapy a plus but not required. A minimum of 5-8+ years of post-doctoral and/or industry experience in biotech or pharma, with a proven track record of advancing IO programs. Deep understanding of immunology, particularly T cell biology highly desirable. Deep biological understanding of hematological malignancies and the unique tumor immune microenvironment of the blood and bone marrow. Experience working with multiple dimensional data, extract biological insights from data highly desirable. Exceptional written and verbal communication skills, with the ability to distill complex data into clear, actionable strategic decisions. #Li-JR1 #Li-Contract Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech. EEO Statement It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or a ... (truncated, view full listing at source)